Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan…
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Runway Growth Capital LLC is a leading U.S.-based specialty finance lenderRelationship further strengthens Company's balance sheet ahead of pending FDA approval and expected Q4 launch of ARC-EX System in the U.S. EINDHOVEN, the Netherlands, June28, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company...
Nasdaq GlobeNewswire
28/06/2024
Information on the total number of voting rights and shares
REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,904,962.41 Total number of securities carrying voting rights: 34,373,015 (all ordinary...
Nasdaq GlobeNewswire
28/06/2024
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
thfloor, 75013 Paris, France.At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent with the recommendations of the management.The detailed results of the vote and the resolutions are available on Cellectis' website: https://www.cellectis.com/en/investors/general-meetings/About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform...
Nasdaq GlobeNewswire
28/06/2024
Higher cantonal composition authority issues written court decision in respect…
Allschwil, Switzerland – June 28, 2024Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority(obere kantonale Nachlassbehörde)(the Court) in respect to the approval of the amendments of the terms of its outstanding convertible bonds originally maturing on July 17, 2024 (ISIN: CH0426820350) decided at the bondholder meeting held on May 6, 2024.If no appeal is filed within the statutory period of 30 days, the...
Nasdaq GlobeNewswire
28/06/2024
Results of the Combined General Meeting of 28 June 2024
Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections,announces the results of the shareholder vote following the Combined General Meeting held today, 28 June 2024, at the head office, located 60 avenue Rockefeller, 69008, Lyon.The shareholders approved all the resolutions on which the Board of Directors recommended a...
Nasdaq GlobeNewswire
28/06/2024
Pierre Fabre Laboratories announce granting of European marketing authorization…
The decision of the EC follows the favorable opinion issued on April 25 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). It is based on the results of two pivotal, multicenter, double-blind, randomized phase 3 studies in adults with overactive bladder symptoms. Study RVT-901-3003 (EMPOWUR) evaluated the efficacy, tolerability, and safety of vibegron (at a dose of 75 mg per day) over 12 weeks compared to placebo and with tolterodine as a…
PR Newswire
28/06/2024
Zealand Pharma major shareholder announcement: Van Herk Investments
Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk InvestmentsCopenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 28 June 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:As...
Nasdaq GlobeNewswire
28/06/2024
Total number of shares and voting rights in Zealand Pharma at June 28, 2024
Company announcement – No. 37 / 2024 Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Copenhagen, Denmark, June 28, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of...
Nasdaq GlobeNewswire
28/06/2024
Tiziana Receives $3.4 Million in Non-Dilutive Funding
here. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, “Tiziana is pleased to receive $3.4 million in non-dilutive funding to support our ongoing Phase 2 trial of intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS) as well as our work in Alzheimer's Disease. We continue to explore all avenues to pursue further non-dilutive funding in the near term.” About Foralumab Activated T cells play an important role in the...
Nasdaq GlobeNewswire
28/06/2024
CO2 AI Launches First Solution to Compute Product Emissions at Scale
Traditional methods like manual Life Cycle Assessments (LCAs) are slow, inconsistent, and costly. According to the 2023 Carbon Survey by CO2 AI and Boston Consulting Group (BCG), only 38% of companies receive adequate product-level data from suppliers. Traditional methods like manual Life Cycle Assessments (LCAs) are slow, inconsistent, and costly. According to the 2023 Carbon Survey by CO2 AI and Boston Consulting Group (BCG), only 38% of companies receive adequate product-level data from...
PR Newswire
28/06/2024
Veterinary Ultrasound Market to Reach USD 539 Million by 2029: Trends, Drivers…
Browse in-depth TOC on "Veterinary Ultrasound Market" Browse in-depth TOC on "Veterinary Ultrasound Market" 230 - Tables 52 - Figures 250 - Pages Key Drivers and Challenges Factors propelling market growth include increasing pet ownership and healthcare spending, advancements in technology, growing awareness of animal health, and rising livestock populations. Challenges include the high cost of advanced devices, scarcity of skilled professionals, economic constraints in...
PR Newswire
28/06/2024
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccineEmergency Use Authorization for the MVA-BN vaccine has been issued in the DR CongoCOPENHAGEN, Denmark, June 28, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced an extended commitment to help fight the current mpox outbreak in Africa. The Company's MVA-BN vaccine, the only FDA and EMA-approved mpox vaccine, which served as an important...
Nasdaq GlobeNewswire
28/06/2024
Roche's Vabysmo gets CHMP recommendation for third indication retinal vein…
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept If approved, Vabysmo would be the first and only bispecific antibody treatment available for the nearly one million people with RVO in the European UnionVabysmo is already approved in the US and Japan for RVO and in more than 95 countries around the world for people living with nAMD...
Nasdaq GlobeNewswire
28/06/2024
Endo Announces Commencement of OTCQX Trading
The OTCQX Market offers a valuable and convenient trading experience for U.S. investors, brokers and institutions. It is the premier market of OTC Markets Group, which is designed for established, investor-focused companies worldwide. Eligibility for trading on this platform requires companies to fulfill stringent financial and governance standards, adhere to U.S. securities laws, and maintain transparent and current disclosure. The OTCQX Market offers a valuable and convenient trading…
PR Newswire
28/06/2024
CHMP recommends EU approval of Roche's PiaSky for people with PNH, a rare…
If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide an alternative to existing intravenous (IV) C5 inhibitors, potentially helping to reduce treatment burden 1 The recommendation is based on the COMMODORE 2 study results, where SC PiaSky given every month demonstrated equivalent disease control and comparable safety to IV eculizumab...
Nasdaq GlobeNewswire
28/06/2024
AB Science provides an update on the application for conditional marketing…
PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISParis, 28 June, 2024, 12:30pm CETAB Science SA(Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of...
Nasdaq GlobeNewswire
28/06/2024
SPINEART APPOINTS LAURENT NODÉ-LANGLOIS AS CHIEF TECHNOLOGY OFFICER TO LEAD…
Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at General Electric, playing a pivotal role in advancing GE Healthcare's 3D imaging and navigation technologies. Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at...
PR Newswire
28/06/2024
SciBase partner with a large health care group in Los Angeles, Unified Health…
"SciBase and Unified Health are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes," says Pia Renaudin, CEO of SciBase. "We are encouraged to see more patients getting access to our point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable." "SciBase and Unified Health are well aligned with a shared mission to provide clinicians…
PR Newswire
28/06/2024
Zealand Pharma completes registration of capital increase
Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increaseNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT...
Nasdaq GlobeNewswire
28/06/2024
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of…
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ®NHL-1 studyFL is the second most common type of NHL and accounts for approximately 20-30 percent of all global casesIf approved, epcoritamab (TEPKINLY ® ) would become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after...
Nasdaq GlobeNewswire
28/06/2024
Gerresheimer: New pictures available
Media Contact Media Contact Jutta LorbergHead of Corporate CommunicationT +49 211 6181
[email protected]
View original content: https://www.prnewswire.co.uk/news-releases/gerresheimer-new-pictures-available-302184778.html
PR Newswire
28/06/2024
Hansa Biopharma: increase in number of shares and votes
This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 28, 2024 at 07:00 CEST. This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through...
PR Newswire
28/06/2024
BioSenic S.A. : Information on the total number of voting rights and shares
PRESS RELEASE – REGULATED INFORMATIONMont-Saint-Guibert, Belgium, June 28, 2024, 7.00 am CET –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication...
Nasdaq GlobeNewswire
28/06/2024
Natalia Vodianova Invests in Swiss Beauty and Longevity Brand NIANCE
NIANCE is a Zurich-based luxury skincare and nutritional supplement brand, Switzerland's best-kept secret in beauty and longevity. Celebrated for its groundbreaking biotechnology, FERNESSE™, this technology enables the release of the full Triple-Biotic power (prebiotics, probiotics, and postbiotics) of its active ingredients, significantly increasing the bioavailability of nutrients. By addressing the root cause of aging, NIANCE combines the finest natural ingredients from the Swiss Alps with…
PR Newswire
28/06/2024
Altri Comunicati